Chanzá NM, et al. - Researchers undertook a multicentre, international, retrospective cohort study of patients with metastatic non-clear-cell renal cell carcinoma treated with oral cabozantinib during any treatment line at 22 centers (21 in the USA and one in Belgium) to investigate the antitumor activity and toxicity of cabozantinib in advanced non-clear-cell renal cell carcinoma. They identified 112 patients with non-clear-cell renal cell carcinoma treated at the participating centres, 66 (59%) with papillary histology, 17 (15%) with Xp11.2 translocation histology, 15 (13%) with unclassified histology, ten (9%) with chromophobe histology, and four (4%) with collecting duct histology. This real-world study suggests cabozantinib as safe and has antitumor activity across non-clear-cell renal cell carcinomas. To enhance outcomes across these rare diseases with few evidence-based treatment options, they support continued support of international collaborations and prospective ongoing studies targeting non-clear-cell renal cell carcinoma subtypes and specific molecular alterations.